Megavog Mf 0.2mg/500mg Tablet belongs to the therapeutic classification of Antidiabetic Agents. The primary composition for this medicine is Metformin 500 MG, Voglibose 0.2 MG.

Megavog MF 0.2/500 Tablet 10's may increase the risk of cardiovascular diseases and hypoglycemic conditions in renal and liver disease patients. It can cause pneumatosis intestinalis (gas-filled cysts on the bowel wall) when used along with other alpha-gastrointestinal drugs. It is advised to monitor the gastrointestinal side effects thoroughly to rule out the possibility of pneumatosis intestinalis. Megavog MF 0.2/500 Tablet 10's has an increased risk of lactic acidosis (a rare, but serious metabolic complication of excess lactic acid in the blood that is caused by metformin accumulation). The risk of lactic acidosis is high in older people with kidney, liver, and heart diseases. Hence, brief your medical history and take advice from your doctor before starting Megavog MF 0.2/500 Tablet 10's. Avoid consuming excessive alcohol as it can potentiate lactic acidosis.